Morningstar's Coeptis Therapeutics Inc Stock Analysis
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Coeptis Therapeutics Inc's Company Profile
Coeptis Therapeutics Inc is a pharmaceutical company focused on the development of innovative therapeutics and technologies that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its product portfolio consists of two clinical-stage drug candidates (CPT1550 and CPT60621), two approved drugs (Conjupri (levamlodipine) tablets and Consensi (amlodipine and celecoxib) tablets) and the product opportunities through its two exclusive option agreements.
Wexford, PA, 15090